BioSpace News Archive

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Wajda v. Patel, et al. , Case: 2019-0122-JTL, a putative shareholder derivative action, was dismissed by Vice Chancellor Laster of the Chancery Court of Delaware . The derivative action was fi

Lemonaid Health, a convenient, affordable, on-demand platform for accessing healthcare online, has raised a $33 million Series B round of funding, bringing total financing to $55 million.

Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced it has completed its revisions to the pre-specified Statistical Analysis Plan (SAP) f

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced strategic changes to restructure its workforce, as it also reached another major milestone in its story with the official opening of a 91,000-square-foot, state-of-the-art factory and expanded service complex in Texas.

- Diagnostic Kit Authorized for Use on Widely Installed RT-PCR Device and High-Throughput RNA Extraction Robotics; Company Ramps Kit Production in Response - STONY BROOK, N.Y.--( BUSINESS WIRE )-- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates, today announc

If followed, guidelines would reduce ability of women and their doctors to choose widely adopted Pap-based testing strategies that have proven highly effective

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is pleased to announce that additional characterization of a subset of fully human, therapeutic antibodies, already shown to have potent neutralizing activity, ar

Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Paul F. Lizzul, M.D., Ph.D. as Chief Medical Officer. “Paul’s extensive expertise in the development of immune-modulating therapeutics will be instrumental to the advancement of Anapty